Epithelial Ovarian Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Epithelial Ovarian Cancer – Pipeline Review, H2 2016’, provides an overview of the Epithelial Ovarian Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epithelial Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epithelial Ovarian Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer

The report reviews pipeline therapeutics for Epithelial Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Epithelial Ovarian Cancer therapeutics and enlists all their major and minor projects

The report assesses Epithelial Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Epithelial Ovarian Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Adaptimmune Therapeutics Plc

Amgen Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Bayer AG

BioNumerik Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Celldex Therapeutics Inc

Celon Pharma Sp z oo

Celsion Corp

CerRx Inc

Cerulean Pharma Inc

Clovis Oncology Inc

Dr. Reddy's Laboratories Ltd

EirGenix Inc.

Eisai Co Ltd

Eli Lilly and Company

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Gene Techno Science Co Ltd

Genentech Inc

Genor BioPharma Co Ltd

Glycotope GmbH

Ignyta Inc

ImmunoGen Inc

Incyte Corp

Innate Immunotherapeutics Ltd

Johnson & Johnson

Juno Therapeutics Inc

Mabion SA

MabVax Therapeutics Holdings Inc

Mateon Therapeutics Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Mycenax Biotech Inc

Novartis AG

Novogen Ltd

Oasmia Pharmaceutical AB

OBI Pharma Inc

Oncobiologics Inc

Oncolix Inc

Oncolytics Biotech Inc

Oxford BioMedica Plc

OXIS International, Inc.

Pharma Mar SA

Prima BioMed Ltd

PsiOxus Therapeutics Ltd

Rgenix Inc

Richter Gedeon Nyrt

Sanofi

Sanofi Pasteur SA

Shenzen SiBiono GeneTech Co., Ltd.

Sotio as

TapImmune Inc

Tara Immuno-Oncology Therapeutics LLC

Tesaro Inc

TetraLogic Pharmaceuticals

Tyrogenex Inc

VentiRx Pharmaceuticals Inc

Verastem Inc

Vyriad Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Epithelial Ovarian Cancer Overview 7

Therapeutics Development 8

Epithelial Ovarian Cancer - Therapeutics under Development by Companies 10

Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 15

Epithelial Ovarian Cancer - Pipeline Products Glance 16

Epithelial Ovarian Cancer - Products under Development by Companies 20

Epithelial Ovarian Cancer - Products under Investigation by Universities/Institutes 26

Epithelial Ovarian Cancer - Companies Involved in Therapeutics Development 27

Epithelial Ovarian Cancer - Therapeutics Assessment 94

Drug Profiles 115

Epithelial Ovarian Cancer - Dormant Projects 480

Epithelial Ovarian Cancer - Discontinued Products 484

Epithelial Ovarian Cancer - Product Development Milestones 485

Appendix 495

List of Tables

List of Tables

Number of Products under Development for Epithelial Ovarian Cancer, H2 2016 19

Number of Products under Development for Epithelial Ovarian Cancer – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Development by Companies, H2 2016 (Contd..1) 22

Number of Products under Development by Companies, H2 2016 (Contd..2) 23

Number of Products under Development by Companies, H2 2016 (Contd..3) 24

Number of Products under Development by Companies, H2 2016 (Contd..4) 25

Number of Products under Investigation by Universities/Institutes, H2 2016 26

Comparative Analysis by Late Stage Development, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Development, H2 2016 29

Comparative Analysis by Unknown Stage Development, H2 2016 30

Products under Development by Companies, H2 2016 31

Products under Development by Companies, H2 2016 (Contd..1) 32

Products under Development by Companies, H2 2016 (Contd..2) 33

Products under Development by Companies, H2 2016 (Contd..3) 34

Products under Development by Companies, H2 2016 (Contd..4) 35

Products under Development by Companies, H2 2016 (Contd..5) 36

Products under Investigation by Universities/Institutes, H2 2016 37

Epithelial Ovarian Cancer – Pipeline by AbbVie Inc, H2 2016 38

Epithelial Ovarian Cancer – Pipeline by Adaptimmune Therapeutics Plc, H2 2016 39

Epithelial Ovarian Cancer – Pipeline by Amgen Inc, H2 2016 40

Epithelial Ovarian Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2016 41

Epithelial Ovarian Cancer – Pipeline by AstraZeneca Plc, H2 2016 42

Epithelial Ovarian Cancer – Pipeline by Atara Biotherapeutics Inc, H2 2016 43

Epithelial Ovarian Cancer – Pipeline by Bayer AG, H2 2016 44

Epithelial Ovarian Cancer – Pipeline by BioNumerik Pharmaceuticals Inc, H2 2016 45

Epithelial Ovarian Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 46

Epithelial Ovarian Cancer – Pipeline by Boston Biomedical Inc, H2 2016 47

Epithelial Ovarian Cancer – Pipeline by Bristol-Myers Squibb Company, H2 2016 48

Epithelial Ovarian Cancer – Pipeline by Celldex Therapeutics Inc, H2 2016 49

Epithelial Ovarian Cancer – Pipeline by Celon Pharma Sp z oo, H2 2016 50

Epithelial Ovarian Cancer – Pipeline by Celsion Corp, H2 2016 51

Epithelial Ovarian Cancer – Pipeline by CerRx Inc, H2 2016 52

Epithelial Ovarian Cancer – Pipeline by Cerulean Pharma Inc, H2 2016 53

Epithelial Ovarian Cancer – Pipeline by Clovis Oncology Inc, H2 2016 54

Epithelial Ovarian Cancer – Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 55

Epithelial Ovarian Cancer – Pipeline by EirGenix Inc., H2 2016 56

Epithelial Ovarian Cancer – Pipeline by Eisai Co Ltd, H2 2016 57

Epithelial Ovarian Cancer – Pipeline by Eli Lilly and Company, H2 2016 58

Epithelial Ovarian Cancer – Pipeline by Esperance Pharmaceuticals Inc, H2 2016 59

Epithelial Ovarian Cancer – Pipeline by Exelixis Inc, H2 2016 60

Epithelial Ovarian Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 61

Epithelial Ovarian Cancer – Pipeline by Gene Techno Science Co Ltd, H2 2016 62

Epithelial Ovarian Cancer – Pipeline by Genentech Inc, H2 2016 63

Epithelial Ovarian Cancer – Pipeline by Genor BioPharma Co Ltd, H2 2016 64

Epithelial Ovarian Cancer – Pipeline by Glycotope GmbH, H2 2016 65

Epithelial Ovarian Cancer – Pipeline by Ignyta Inc, H2 2016 66

Epithelial Ovarian Cancer – Pipeline by ImmunoGen Inc, H2 2016 67

Epithelial Ovarian Cancer – Pipeline by Incyte Corp, H2 2016 68

Epithelial Ovarian Cancer – Pipeline by Innate Immunotherapeutics Ltd, H2 2016 69

Epithelial Ovarian Cancer – Pipeline by Johnson & Johnson, H2 2016 70

Epithelial Ovarian Cancer – Pipeline by Juno Therapeutics Inc, H2 2016 71

Epithelial Ovarian Cancer – Pipeline by Mabion SA, H2 2016 72

Epithelial Ovarian Cancer – Pipeline by MabVax Therapeutics Holdings Inc, H2 2016 73

Epithelial Ovarian Cancer – Pipeline by Mateon Therapeutics Inc, H2 2016 74

Epithelial Ovarian Cancer – Pipeline by MedImmune LLC, H2 2016 75

Epithelial Ovarian Cancer – Pipeline by Merck & Co Inc, H2 2016 76

Epithelial Ovarian Cancer – Pipeline by Merck KGaA, H2 2016 77

Epithelial Ovarian Cancer – Pipeline by Mycenax Biotech Inc, H2 2016 78

Epithelial Ovarian Cancer – Pipeline by Novartis AG, H2 2016 79

Epithelial Ovarian Cancer – Pipeline by Novogen Ltd, H2 2016 80

Epithelial Ovarian Cancer – Pipeline by Oasmia Pharmaceutical AB, H2 2016 81

Epithelial Ovarian Cancer – Pipeline by OBI Pharma Inc, H2 2016 82

Epithelial Ovarian Cancer – Pipeline by Oncobiologics Inc, H2 2016 83

Epithelial Ovarian Cancer – Pipeline by Oncolix Inc, H2 2016 84

Epithelial Ovarian Cancer – Pipeline by Oncolytics Biotech Inc, H2 2016 85

Epithelial Ovarian Cancer – Pipeline by Oxford BioMedica Plc, H2 2016 86

Epithelial Ovarian Cancer – Pipeline by OXIS International, Inc., H2 2016 87

Epithelial Ovarian Cancer – Pipeline by Pharma Mar SA, H2 2016 88

Epithelial Ovarian Cancer – Pipeline by Prima BioMed Ltd, H2 2016 89

Epithelial Ovarian Cancer – Pipeline by PsiOxus Therapeutics Ltd, H2 2016 90

Epithelial Ovarian Cancer – Pipeline by Rgenix Inc, H2 2016 91

Epithelial Ovarian Cancer – Pipeline by Richter Gedeon Nyrt, H2 2016 92

Epithelial Ovarian Cancer – Pipeline by Sanofi, H2 2016 93

Epithelial Ovarian Cancer – Pipeline by Sanofi Pasteur SA, H2 2016 94

Epithelial Ovarian Cancer – Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016 95

Epithelial Ovarian Cancer – Pipeline by Sotio as, H2 2016 96

Epithelial Ovarian Cancer – Pipeline by TapImmune Inc, H2 2016 97

Epithelial Ovarian Cancer – Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 98

Epithelial Ovarian Cancer – Pipeline by Tesaro Inc, H2 2016 99

Epithelial Ovarian Cancer – Pipeline by TetraLogic Pharmaceuticals, H2 2016 100

Epithelial Ovarian Cancer – Pipeline by Tyrogenex Inc, H2 2016 101

Epithelial Ovarian Cancer – Pipeline by VentiRx Pharmaceuticals Inc, H2 2016 102

Epithelial Ovarian Cancer – Pipeline by Verastem Inc, H2 2016 103

Epithelial Ovarian Cancer – Pipeline by Vyriad Inc, H2 2016 104

Assessment by Monotherapy Products, H2 2016 105

Number of Products by Stage and Target, H2 2016 107

Number of Products by Stage and Mechanism of Action, H2 2016 115

Number of Products by Stage and Route of Administration, H2 2016 123

Number of Products by Stage and Molecule Type, H2 2016 125

Epithelial Ovarian Cancer – Dormant Projects, H2 2016 491

Epithelial Ovarian Cancer – Dormant Projects (Contd..1), H2 2016 492

Epithelial Ovarian Cancer – Dormant Projects (Contd..2), H2 2016 493

Epithelial Ovarian Cancer – Dormant Projects (Contd..3), H2 2016 494

Epithelial Ovarian Cancer – Discontinued Products, H2 2016 495

List of Figures

List of Figures

Number of Products under Development for Epithelial Ovarian Cancer, H2 2016 19

Number of Products under Development for Epithelial Ovarian Cancer – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Investigation by Universities/Institutes, H2 2016 26

Comparative Analysis by Late Stage Development, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Products, H2 2016 29

Assessment by Monotherapy Products, H2 2016 105

Number of Products by Top 10 Targets, H2 2016 106

Number of Products by Stage and Top 10 Targets, H2 2016 106

Number of Products by Top 10 Mechanism of Actions, H2 2016 114

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 114

Number of Products by Top 10 Routes of Administration, H2 2016 122

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 122

Number of Products by Top 10 Molecule Types, H2 2016 124

Number of Products by Stage and Top 10 Molecule Types, H2 2016 124

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports